Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells

Neurochemistry International

Volumn 57, Issue 3, 2010, Pages 198-205

  Wu, Yuncheng ^a,b   Li, Xinqun ^c   Xie, Wenjie ^b   Jankovic, Joseph ^b   Le, Weidong ^b   Pan, Tianhong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autophagy; HIF 1 ; Iron chelator; Neuroprotection; Parkinson's disease

Indexed keywords

BECLIN 1; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ROTENONE; ANTIDOTE; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; NEUROPROTECTIVE AGENT; UNCOUPLING PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; HUMAN; METABOLISM; NEUROTOXICITY SYNDROMES; PSYCHOLOGY; TOXICITY; WESTERN BLOTTING;

ANTIDOTES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE; DEFEROXAMINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE PROTEINS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; ROTENONE; UNCOUPLING AGENTS;

EID: 77955094939     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.05.008     Document Type: Article

References (63)

1. Andersen J.K. Iron dysregulation and Parkinson's disease. J. Alzheimers. Dis. 2004, 6:47-52.
2. Benarroch E.E. Brain iron homeostasis and neurodegenerative disease. Neurology 2009, 72:1436-1440.
3. Bi J., Jiang B., Hao S., Zhang A., Dong Y., Jiang T., An L. Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. Neurochem Int. 2009, 54(3-4):264-270.
4. Bohensky J., Shapiro I.M., Leshinsky S., Terkhorn S.P., Adams C.S., Srinivas V. HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway. Autophagy 2007, 3:207-214.
5. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes. Dev. 2004, 18:2893-2904.
6. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
7. Chen Y., McMillan-Ward E., Kong J., Israels S.J., Gibson S.B. Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J. Cell. Sci. 2007, 120:4155-4166.
8. Cheung Z.H., Ip N.Y. The emerging role of autophagy in Parkinson's disease. Mol Brain 2009, 2:29.
9. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by cgaperone-mediated autophagy. Science 2004, 305:1292-1295.
10. Cunningham M.J., Nathan D.G. New developments in iron chelators. Curr Opin Hematol 2005, 12:129-134.
11. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
12. Ehrenreich H., Aust C., Krampe H., Jahn H., Jacob S., Herrmann M., Sirén A.L. Erythropoietin: Novel Approaches to Neuroprotection in Humman Brain Disease. Metab. Brain. Dis. 2004, 19:195-206.
13. Freeman R.S., Barone M.C. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr. Drug. Targets. CNS. Neurol. Disord. 2005, 4:85-92.
14. Hagen T., Taylor C.T., Lam F., Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003, 302:1975-1978.
15. Hardie D.G. New roles for the LKB1-->AMPK pathway. Curr. Opin. Cell. Biol. 2005, 17:167-173.
16. Irrcher I., Park D.S. Parkinson's disease: to live or die by autophagy. Sci. Signal. 2009, 2:21.
17. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
18. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A.v., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
19. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO. J. 2000, 19:5720-5728.
20. Kimbro K.S., Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer. 2006, 13:739-749.
21. Korczyn A.D., Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 2002, 62:775-786.
22. Larsen T.R., Söderling A.S., Caidahl K., Roepstorff P., Gramsbergen J.B. Nitration of soluble proteins in organotypic culture models of Parkinson's disease. Neurochem Int. 2008, 52(3):487-494.
23. Lee J.A. Autophagy in neurodegeneration: two sides of the same coin. BMB Rep 2009, 42:324-330.
24. Lu Y., Liang K., Li X., Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1. Mol. Cancer. 2007, 6:63.
25. Malkus K.A., Tsika E., Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener. 2009, 4:24.
26. Mateo J., García-Lecea M., Cadenas S., Hernández C., Moncada S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. 2003, 376:537-544.
27. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease, a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
28. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO. J. 2001, 20:5197-5206.
29. McLachlan D.R.C., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
30. Milosevic J., Maisel M., Wegner F., Leuchtenberger J., Wenger R.H., Gerlach M., Storch A., Schwarz J. Lack of Hypoxia-Inducible Factor-1α Impairs Midbrain Neural Precursor Cells Involving Vascular Endothelial Growth Factor Signaling. J. Neurosci. 2007, 27:412-421.
31. Milosevic J., Adler I., Manaenko A., Schwarz S.C., Walkinshaw G., Arend M., Flippin L.A., Storch A., Schwarz J. Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF-alpha): relevance in neural progenitor/stem cells. Neurotox Res. 2009, 15(4):367-380.
32. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature. 2008, 451(7182):1069-1075.
33. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
34. Ostrerova-Golts N., Petrucelli L., John, Hardy J., Lee J.M., Farer M., Wolozin B. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity. J. Neurosci. 2000, 20:6048-6054.
35. Pan T., Li X., Xie W., Jankovic J., Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 2005, 579:6716-6720.
36. Pan T., Kondo S., Le W., Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008, 131:1969-1978.
37. Pan T., Kondo S., Zhu W., Xie W., Jankovic J., Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol. Dis. 2008, 32:16-25.
38. Pan T., Rawal P., Wu Y., Xie W., Jankovic J., Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 2009, 164:541-551.
39. Rami A. Review: autophagy in neurodegeneration: firefighter and/or incendiarist?. Neuropathol. Appl. Neurobiol. 2009, 35:449-461.
40. Ravikumar B., Berger Z., Vacher C., O'Kane C.J., Rubinsztein D.C. Rapamycin pre-treatment protects against apoptosis. Hum. Mol. Genet. 2006, 15:1209-1216.
41. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
42. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell. Dev. Biol. 1999, 15:551-578.
43. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 2003, 3:721-732.
44. Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., Patton S.M., Connor J.R., Cherny R.A., Volitakis I., Bush A.I., Langsetmo I., Seeley T., Gunzler V., Ratan R.R. Hypoxia-inducible factor prolyl 4-Hydroxylase inhibition a target for neuroprotection in the central nervous system. J Biol Chem. 2005, 280:41732-41743.
45. Signore A.P., Weng Z., Hastings T., Van Laar A.D., Liang Q., Lee Y.J., Chen J. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J. Neurochem. 2006, 96:428-443.
46. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65:3336-3346.
47. Tian Y.Y., Tang C.J., Wang J.N., Feng Y., Chen X.W., Wang L., Qiao X., Sun S.G. Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci. Lett. 2007, 421:239-244.
48. Tolkovsky A.M. Mitophagy. Biochim. Biophys. Acta 2009, 1793:1508-1515.
49. Tolkovsky A.M., Xue L., Fletcher G.C., Borutaite V. Mitochondrial disappearance from cells: a clue to the role of autophagy in programmed cell death and disease?. Biochimie 2002, 84:233-240.
50. Thomas R., Kim M.H. Targeting the hypoxia inducible factor pathway with mitochondrial uncouplers. Mol. Cell. Biochem. 2007, 296:35-44.
51. Tomita S., Ueno M., Sakamoto M., Kitahama Y., Ueki M., Maekawa N., Sakamoto H., Gassmann M., Kageyama R., Ueda N., Gonzalez F.J., Takahama Y. Defective brain development in mice lacking the Hif-1α gene in neural cells. Mol. Cell. Biol. 2003, 23:6739-6749.
52. Verma R., Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem Int. 2009, 55(6):369-375.
53. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J. Cereb. Blood. Flow. Metab. 2009, 29:230-234.
54. Wenger R.H. Mammalian oxygen sensing, signalling and gene regulation. J. Exp. Biol. 2000, 203:1253-1263.
55. Wolozin B., Golts N. Iron and Parkinson's disease. Neuroscientist 2002, 8:22-32.
56. Xue Y.Q., Zhao L.R., Guo W.P., Duan W.M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 2007, 146:1245-1258.
57. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell. Struct. Funct. 1998, 23:33-42.
58. Yasuhara T., Shingo T., Muraoka K., Kameda M., Agari T., Wen, Ji Y., Hayase H., Hamada H., Borlongan C.V., Date I. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain. Research. 2005, 1053:10-18.
59. Youdim M.B., Stephenson G., Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 2004, 1012:306-325.
60. Zhang X., Xie W., Qu S., Pan T., Wang X., Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 2005, 333:544-549.
61. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., Gonzalez F.J., Semenza G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903.
62. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005, 13(3):773-783.
63. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB. J. 2007, 21:3835-3844.